Analytical Data
-
Gene name
MET
- Application
-
Alternative Names
HGFR; RCCP2; Hepatocyte Growth Factor Receptor; Met Proto-Oncogene; Mesenchymal-Epithelial Transition Factor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; Tyrosine-protein kinase M
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08581
-
Expression Region
Val1092~Val1379
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The MET receptor tyrosine kinase, encoded by the MET gene, plays a crucial role in various cellular processes, including cell growth, motility, and survival. Its activation by hepatocyte growth factor (HGF) promotes several biological functions that are vital for normal development and tissue repair. However, aberrant MET signaling is implicated in various pathological conditions, particularly in cancer, where MET overexpression or mutations can lead to enhanced tumor progression, metastasis, and resistance to therapies. As a result, MET has emerged as a significant target for drug development in oncology. Research on MET recombinant proteins aims to better understand its structural and functional characteristics, allowing for the design of inhibitors that can effectively block its activity. Additionally, studying MET recombinant proteins can provide insights into the mechanisms of receptor activation and downstream signaling pathways, contributing to a more comprehensive understanding of the role of MET in both normal physiology and the pathogenesis of diseases. Investigations involving MET recombinant proteins not only facilitate the identification of potential therapeutic interventions but also hold promise for biomarker development, improving patient stratification and personalized medicine approaches in cancer treatment.
